39 results about "Prostate cell" patented technology

The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

An apparatus and a method for treatment of benign prostatic hyperplasia are disclosed. The apparatus includes an applicator piece carrying a set of electrodes shaped and positioned to create a substantial electric field in the volume of hyperplasia and a pulse generator adapted for delivery of electrical pulses above the upper electroporation limit for the neoplastic cells. The amplitude, duration and number of the electrical pulses are generally selected to cause necrosis of a significant fraction of the volume of benign prostatic hyperplasia. The apparatus may include a high frequency system for heating the prostatic tissue and a cooling system for cooling the urethra. The combined action of heating and cooling may increase the temperature of the prostate cells to 45 degrees C. to 55 degrees C., while keeping the urinary tract at a temperature 15 degrees C. to 20 degrees C. This temperature distribution can increase the selectivity of the treatment by increasing susceptibility of the neoplastic cells to the electroporation treatment and decreasing it for the normal urethral tissues.

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

The present invention relates to a method capable of using natural and artificial synthetic isosulfocyanate compound or its derivative to prevent and cure prostatic diseases and skin carcinoma. The internal tests show that various isosulfocyanate compounds or their derivatives can induce prostatic cell II phase drug metabolic detoxication enzyme-glutathione transferase so as to can inhibit the hyperplasia of prostate and inflammation, and can prevent and cure prostatic carcinoma and skin carcinoma.

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

The present invention provides methods of detecting prostate cancer employing biomarkers, including hZIP1, zinc and citrate. Also provided are antibodies to detect hZIP1 protein or peptides and an expression vector comprising a genetic sequence effective to increase uptake of zinc into a prostate cell upon expression thereof. Furthermore, methods of treating prostate cancer and of increasing uptake of zinc into a prostate cell are provided.

Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

Disclosed are methods for diagnosing, monitoring the progression of, and treating a prostate disorder based upon genes that are differentially expressed in prostate disorders. Also disclosed are methods for identifying agents useful in the treatment of a prostate disorder, methods for monitoring the efficacy of a treatment for a prostate disorder, methods for inhibiting the proliferation of a prostate cell, and prostate-specific vectors including the promoter of these genes.

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.

Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.

The invention discloses a method for detecting prostate cancer exosome based on Fe3O4@ SiO2@ TiO2 nanoparticle enrichment and a PSMA sensor. The method comprises the following steps of: enriching exosome by adopting Fe3O4@ SiO2@ TiO2 nanoparticles, and then constructing a hairpin-shaped PSMA aptamer sensor to quantify the exosome by measuring the change of fluorescence intensity. By utilizing thedetection method, the exosome of prostate cancer cells can be successfully distinguished from the exosome of normal prostate cells, and the detection limit is 9 * 10 <3> exosomes / microliter. The method is used for clinical prostate cancer patient serum samples and normal human serum samples, can quickly and accurately detect prostate cancer patients, and is verified by a traditional ELISA method. The exosome enrichment method is simple and quick, the enrichment efficiency is high, exosome enrichment can be completed within 8 minutes, and the enrichment efficiency is 91.5%. The sensitivity ishigh, the specificity is high, the detection limit is 9 * 10 <3> exosomes / microliter, and clinical prostate cancer patients and healthy people can be remarkably distinguished.

The invention provides regulatory constructs comprising intron 3 of the prostate specific membrane antigen gene (PSMA). An isolated nucleic acid molecule encoding the partial sequence of intron 3 of PSMA, a vector and a recombinant expression cassette are disclosed. The invention also provides a method of directing expression of a coding sequence in a prostate cell, a bladder cell, a breast cell and a vascular endothelial cell using the said constructs. This invention further provides a method of treatment of cancer using the said constructs.

The invention belongs to the technical field of medical biology, and discloses a molecular marker-LncRNA SNHG11 for auxiliary diagnosis of prostatic cancer. The LncRNA SNHG11 is highly expressed in cancer tissues of prostatic cancer, and is lowly expressed in paracancerous normal tissues; moreover, the expression level of the LncRNA SNHG11 in a prostatic cancer cell line is obviously higher than that of a normal prostate cell line; proliferation, migration and invasion of prostatic cancer cells can be obviously inhibited by knocking down the expression level of the LncRNA SNHG11 gene. Therefore, the LncRNA SNHG11 can be used as a molecular marker for auxiliary diagnosis of the prostatic cancer; by detecting the expression level of the LncRNA SNHG11 in a sample, auxiliary diagnosis can be carried out on the prostatic cancer, and a reference basis is provided for clinical doctors to diagnose the prostatic cancer.

The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and / or TAAs that are shared with the antigens present in patients' tumour. In each case, tumour cells are utilised as the starting point on the premise that only rumour cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines. For prostate cancer, for example, a vaccine may be based on one or a combination of different immortalised normal cell lines derived from the prostate. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent prior to use in the mammal or human.

The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, miR-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, miR-374b-5p, miR-615-3p and miR-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among prostate cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients.

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products.

Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.

Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed.

The invention relates to a tumor targeted diagnosis and treatment integrated drug compound, in particular to an <18 / 19>F-labeled PSMA targeted diagnosis and treatment integrated small molecular drug conjugate, a preparation method and an application of the <18 / 19>F-labeled PSMA targeted diagnosis and treatment integrated small molecular drug conjugate. By utilizing a PSMA targeted small molecular ligand, a DM1 drug with a high toxicity killing effect is delivered to PSMA positive prostate cancer cells in a targeted manner, the effect of effectively killing castration-resistant prostate CRPC cells with relative drug resistance is expected to be achieved, besides, the toxic and side effects of the DM1 on the whole body are effectively controlled and reduced, and the tolerance of a patient is improved; and besides, on the basis, a tumor diagnosis and treatment integrated mode is introduced, molecular imaging diagnosis is used for assisting in visualizing the in-vivo transfer process of drugs, predicting the curative effect of the patient, knowing the in-vivo distribution of the drugs, achieving real-time monitoring and individualized administration of the tumor treatment effect and achieving diagnosis and treatment integration.

The invention relates to prostate extracellular substrate gel for cultivating prostate cells. The prostate extracellular matrix gel has the advantages that the prostate extracellular matrix gel is white and semi-transparent and is excellent in biocompatibility; the human prostate epithelial cells can be cultivated by the aid of the prostate extracellular matrix gel and are in tufted three-dimensional spatial growth modes which are consistent with in-vivo cell growth physiological status of mammals, and accordingly in-vivo natural growth environments for the cells in the mammals can be effectively simulated; proliferative stages are long (11 days) and are prolonged by 6 days as compared with proliferative stages of cells cultivated in the prior art.

Disclosed herein are polypeptide molecules having Prostate apoptosis response-4 (Par-4) pro-apoptotic activity in cancer cells and enhanced biological half-life, and related methods. Specifically, the disclosure provides a composition comprising Par-4 polypeptide fusion protein, and a method of inducing apoptosis in a cancer cell using the composition, wherein the cancer cell is metastatic.

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic prostate cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating prostate cancer and non-cancerous disease states in prostate, identifying prostate tissue, monitoring and identifying and / or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered prostate tissue for treatment and research.

The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.

A novel prostate cancer marker is described that is found in cancerous and normal prostate cells of individuals that have prostate cancer but is not found in the prostate of individuals without prostate cancer. The marker also is present in normal tissue adjacent to tumor tissue in individuals having prostate cancer. The marker, however, is absent in the prostate of individuals without prostate cancer. Methods employing the novel prostate cancer marker of the invention to predict the occurrence of the prostate disease, monitor the progression of prostate cancer and effect the treatment of prostate cancer, also are described.

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STRAP” (Serpentine TRansmembrane Antigens of the Prostate). Four particular human STRAPs are described and characterized herein. The human STRAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STRAP family, STRAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STRAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STRAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STRAP-1 is highly over-expressed in certain other human cancers.